Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 28 04:00PM ET
14.02
Dollar change
-0.40
Percentage change
-2.77
%
IndexRUT P/E14.60 EPS (ttm)0.96 Insider Own4.01% Shs Outstand57.33M Perf Week-6.22%
Market Cap807.13M Forward P/E6.34 EPS next Y2.21 Insider Trans0.36% Shs Float55.27M Perf Month-16.84%
Income55.30M PEG- EPS next Q0.40 Inst Own94.63% Short Float5.17% Perf Quarter-19.33%
Sales1.12B P/S0.72 EPS this Y-29.77% Inst Trans-2.10% Short Ratio5.73 Perf Half Y-19.66%
Book/sh-13.78 P/B- EPS next Y5.36% ROA4.58% Short Interest2.85M Perf Year-55.67%
Cash/sh5.19 P/C2.70 EPS next 5Y- ROE- 52W Range12.72 - 33.07 Perf YTD-25.94%
Dividend Est.0.56 (3.99%) P/FCF- EPS past 5Y- ROI6.54% 52W High-57.61% Beta0.75
Dividend TTM0.60 (4.28%) Quick Ratio1.75 Sales past 5Y0.35% Gross Margin66.55% 52W Low10.22% ATR (14)0.77
Dividend Ex-DateFeb 27, 2024 Current Ratio2.20 EPS Y/Y TTM-65.20% Oper. Margin18.91% RSI (14)33.16 Volatility4.29% 5.39%
Employees2200 Debt/Eq- Sales Y/Y TTM0.58% Profit Margin4.93% Recom3.75 Target Price16.50
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-43.30% Payout49.22% Rel Volume0.81 Prev Close14.42
Sales Surprise4.67% EPS Surprise34.07% Sales Q/Q0.58% EarningsFeb 09 BMO Avg Volume497.89K Price14.02
SMA20-11.03% SMA50-17.65% SMA200-25.92% Trades Volume402,215 Change-2.77%
Date Action Analyst Rating Change Price Target Change
Oct-20-23Initiated Wolfe Research Peer Perform
Jan-06-23Downgrade Morgan Stanley Equal-Weight → Underweight $28
Sep-08-22Initiated BTIG Research Neutral
Aug-01-22Initiated Morgan Stanley Equal-Weight $33
Jun-21-22Initiated BofA Securities Underperform $25
Feb-10-24 08:55AM
Feb-09-24 10:07PM
11:43AM
07:45AM
07:07AM
06:30AM Loading…
06:30AM
06:00AM
Feb-07-24 05:00PM
Jan-24-24 05:00PM
Jan-21-24 08:33AM
Jan-09-24 06:00AM
Dec-14-23 05:00PM
Dec-01-23 06:00AM
05:13AM
Nov-29-23 05:00PM
09:34AM Loading…
Nov-22-23 09:34AM
Nov-21-23 07:23AM
07:15AM
07:13AM
05:30AM
05:00AM
Nov-14-23 10:00AM
Oct-31-23 06:50AM
Oct-25-23 05:00PM
Sep-28-23 08:10PM
Sep-06-23 05:00PM
Aug-11-23 06:08AM
Aug-08-23 10:19PM
06:30AM
06:00AM
05:00PM Loading…
Jul-11-23 05:00PM
Jun-30-23 06:15AM
Jun-21-23 08:00PM
May-20-23 08:26AM
May-15-23 05:38PM
05:00PM
09:30AM
09:30AM
May-13-23 08:16AM
12:05AM
May-12-23 06:30AM
06:15AM
06:00AM
May-01-23 01:08PM
Apr-26-23 08:00PM
Apr-22-23 07:20AM
Apr-21-23 06:15PM
Apr-20-23 05:00PM
Mar-26-23 08:45AM
Mar-22-23 06:46AM
Mar-10-23 10:32AM
Feb-24-23 10:00AM
05:50AM
Feb-22-23 05:00PM
Feb-16-23 07:28AM
Feb-15-23 04:53PM
05:32AM
Feb-14-23 06:54PM
12:08PM
06:30AM
06:00AM
Feb-08-23 05:00PM
Jan-30-23 01:25PM
Jan-25-23 07:00AM
Jan-24-23 05:00PM
Jan-21-23 06:16PM
Dec-20-22 11:34AM
10:29AM
06:30AM
06:00AM
Dec-14-22 05:00PM
Nov-08-22 10:03AM
Nov-07-22 06:50AM
Nov-03-22 05:00PM
Nov-01-22 06:50AM
Sep-16-22 04:30PM
Sep-14-22 06:00AM
Aug-18-22 05:00PM
Aug-15-22 06:30AM
06:00AM
Aug-05-22 09:01AM
Jul-05-22 05:00PM
Jun-29-22 12:06PM
May-13-22 06:30AM
May-09-22 04:05PM
Apr-19-22 06:50AM
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Melcher David FDirectorFeb 12Buy16.252,00032,50045,080Feb 12 07:08 PM
Melcher David FDirectorSep 08Buy15.776,23398,27127,698Sep 08 09:47 PM
Kurdikar DevdattPresident and CEOAug 10Buy21.815,000109,050244,791Aug 10 05:11 PM
Mann Jeffrey ZSVP, GC, Head Corp. Dev., SecyAug 10Buy21.674,700101,84955,333Aug 10 05:10 PM
Elguicze JacobSVP and CFOAug 10Buy21.664,625100,19566,027Aug 10 05:09 PM